Frequency Therapeutics Inc (KRRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Frequency Therapeutics Inc (KRRO) has a cash flow conversion efficiency ratio of -0.173x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.18 Million) by net assets ($99.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Frequency Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Frequency Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read KRRO total liabilities for a breakdown of total debt and financial obligations.
Frequency Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Frequency Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HLS Therapeutics Inc
TO:HLS
|
0.040x |
|
Scully Royalty Ltd
NYSE:SRL
|
0.009x |
|
Clarus Corp
NASDAQ:CLAR
|
-0.025x |
|
AleAnna, Inc. Class A Common Stock
NASDAQ:ANNA
|
0.154x |
|
Adda Corporation
TWO:3071
|
0.068x |
|
Ruentex Materials Co Ltd
TW:8463
|
0.186x |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
0.008x |
|
Chateau International Development Co Ltd
TW:2722
|
0.005x |
Annual Cash Flow Conversion Efficiency for Frequency Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Frequency Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see KRRO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $160.41 Million | $-60.07 Million | -0.374x | +5.43% |
| 2023-12-31 | $169.91 Million | $-67.28 Million | -0.396x | -173.10% |
| 2022-12-31 | $-99.03 Million | $-53.65 Million | 0.542x | +320.81% |
| 2021-12-31 | $130.82 Million | $-32.09 Million | -0.245x | -4.50% |
| 2020-12-31 | $192.49 Million | $-45.19 Million | -0.235x | -214.83% |
| 2019-12-31 | $167.36 Million | $34.22 Million | 0.204x | -46.55% |
| 2018-12-31 | $-44.51 Million | $-17.02 Million | 0.382x | -22.42% |
| 2017-12-31 | $-29.64 Million | $-14.61 Million | 0.493x | -- |
About Frequency Therapeutics Inc
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oli… Read more